Aging is a complex continuous multifactorial process leading to loss of function and crystalizing 18 into the many age-related diseases. Here, we explore the arguments for classifying aging as a 19 disease in the context of the upcoming World Health Organization's 11th International Statistical 20 Classification of Diseases and Related Health Problems (ICD-11), expected to be finalized in 21 2018. We hypothesize that classifying aging as a disease will result in new approaches and 22 business models for addressing aging as a treatable condition, which will lead to both economic 23 and healthcare benefits for all stakeholders. Classification of aging as a disease may lead to more 24 efficient allocation of resources by enabling funding bodies and other stakeholders to use 25 quality-adjusted life years (QALYs) and healthy-years equivalent (HYE) as metrics when 26 evaluating both research and clinical programs. We propose forming a Task Force to interface 27 the WHO in order to develop a multidisciplinary framework for classifying aging as a disease.
classifying aging as a disease, as many stakeholders would prefer to have a more granular view 138 into causes of death.
140
To illustrate these differences in opinion about aging, a recent survey in Finland assessed 141 stakeholders' perspectives on what constitutes a disease. The study surveyed 3,000 laypeople, 142 1,500 doctors, 1,500 nurses and 200 parliament members and asked them to rate 60 "states of 143 being" by their perception of disease. And while most cancers like breast cancer (#1) and 144 prostate cancer (#2) were clearly classified as diseases, wrinkles (#60), smoking (#59) and 145 ageing (#58) were not classified as diseases (Tikkinen et al., 2012) . Most of the doctors and 146 nurses did not consider sarcopenia, age-related muscle loss (#31) as a disease. Surprisingly, 147 obesity (#50), was not considered to be a disease by any of the stakeholder groups even though it 148 is now classified as a disease with multiple disease codes (E65-E68) in endocrine, nutritional and 149 metabolic diseases (E00-E90), representing a considerable part of chapter IV in Health Organization, 2011). The case of obesity provides clues that the opinion of multiple 151 stakeholders including medical, general public, doctors and nurses may deviate from the WHO 152 consensus for the purposes of disease classification, and other stakeholders may play a larger 153 role in forming ICD revisions.
155
In another survey of pension funds, insurance companies, and employee benefits industries; only 156 11% of respondents felt that aging is a disease and less than 22% used simulations involving 157 biomedical advances in forecasting life expectancy (Zhavoronkov, 2015) . Considering the 158 relatively conservative responses, these stakeholder groups may not be in favor of classifying 159 aging as a disease in the ICD-11 revision.
161
The debate on whether aging should be classified as a disease is taking place primarily in 162 academic circles (Ries, 1976; Glasser, 1986; Williams, 1987; Blumenthal, 1993; Callahan and 163 Topinkova, 1998; Blumenthal, 2003; Faragher, 2015; Gems, 2015b) with no consensus opinion 164 (Garber, 2008; Donmez and Guarente, 2010) and even some opposing views from 165 biogerontologists (Ardeljan and Chan, 2013; Rattan, 2014) . Even though some of these views aim 166 at higher citation rating or other objectives, these opposing views do not propose concrete plans 167 for addressing the aging problem at the level of WHO.
169
Prior history with many mental disorders, including autism (Lord and Jones, 2012), demonstrates 170 that classifying a state of being as a disease leads to an increased attention to the subject, the 171 development of more accurate diagnostic methods, and increased involvement of the 172 pharmaceutical industry and policy makers. It also provides the basis for clinical trials.
174
Strategies in moving forward 175 176 Large scale studies in humans. There are many strategies that can be pursued to test the efficacy Aging biomarkers. Even though major advances have been made since the final ICD-10 meeting 185 in tracking aging at all levels of organization (Sprott, 2010; Le Couteur et al., 2012; Hatse et al., 186 2014; Wu et al., 2015) , there is no universal set of biomarkers and guidelines for measuring aging 187 as a system. However, in order to successfully evaluate the effect of any drug that influences 188 aging, it is essential have a measureable endpoint, such as biomarkers. Gerontologists have 189 previously struggled to extrapolate biomarkers from animal models to humans (Butler et al., Since the transition from age-associated processes to disease is unclear (Figure 1 ), in the absence 206 of readily available and highly personalized biomarkers, one of the approaches to set the gold 207 standard for health, is to select the age when peak performance is observed in the majority of the 208 population. There are conflicting theories without convincing empirical evidence that the human 209 skeleton stops growing at approximately the age of 20 (Nilsson et al., 2005) . Peak age for 210 athletic performance depends upon sports disciplines and is usually in the range of 20-30 years 211 with younger age of peak performance in short distance races and gradually increasing age of 212 peak performance in longer racing distances (Elmenshawy et al., 2015) . In prenatal diagnostics, 
249
Increasing productive longevity in the developed countries is likely to reduce healthcare costs, 250 boost employee productivity and lead to substantial economic growth (Zhavoronkov and 251 Litovchenko, 2013), while the inability to increase productive longevity quickly may result in 252 economic collapse (Zhavoronkov et al., 2012 ). Yet when it comes to aging, policy makers, the 253 general public, and even pension funds lack the sense of urgency to address it as a curable 254 disease (Zhavoronkov, 2015) even though there is a growing realization of the likely economic 255 problems (Zhavoronkov, 2013) . Even some of the most reputable demographers, gerontologists 256 and biogerontologists express conflicting opinions on the subject, providing arguments against 257 classifying aging as a disease. While these papers promote debate and increase their citation 258 ratings, they are certainly not helpful for making the case for formal classification of aging as a 259 disease or family of diseases. Formal classification of aging as a disease is likely to unite both 260 scientists and medical practitioners in this effort.
262
There are also ethical considerations associated with classifying aging as a disease (Caplan, 263 2005). A large portion of the population may feel uncomfortable with the idea and resist being 264 classified as disease carriers either at birth or after a specific age certain age while lacking clear 265 representation of a disease. However, the recent inclusion of obesity in ICD-10 has shown that it 266 not only helped to attract resources to research, but it also resulted in more frequent diagnosis of 267 the condition. Since obesity has been classified as a disease, it is now easier for medical 268 practitioners to convince patients to pursue healthier lifestyles and prescribe medication, even in 269 cases where patients are comfortable with the condition. Form a task force. As part of the upcoming ICD-11, the International Association for the Study 274 of Pain (IASP) Task Force was created to classify chronic pain as a disease (Treede et al., 2015) , with a clear organizational structure to interact with the WHO to create a classification system of 276 all manifestations of chronic pain, resulting in 7 categories: musculoskeletal pain, visceral pain, 277 headache, neuropathic pain, post surgical and posttraumatic pain, cancer pain and primary pain.
278
A similar task force should be created to interact with the WHO on the classification of aging.
280
Develop an "ideal norm." Despite the growing abundance of biomarkers of aging, classifying 281 aging as a disease will be challenging due to the absence of the "ideal norm." Despite significant 282 effort from the academic and industry communities, sarcopenia is still not classified as a disease 283 despite clear clinical and molecular representation and similarity with premature musculoskeletal 284 aging and myotonic disorders (Cruz-Jentoft et al., 2010; Muscaritoli et al., 2010; Fielding et al., 285 2011; Morley et al., 2011; Mateos-Aierdi et al., 2015) . One approach to address this challenge is 286 to assume an "ideal" disease-free physiological state at a certain age, for example, 25 years of 287 age, and develop a set of interventions to keep the patients as close to that state as possible.
288
Considering the WHO definition of health, it may be possible to agree on the optimal set of 289 biomarkers that would be characteristic to the "state of complete physical, mental and social 290 well-being, not merely the absence of infirmity" and agree on the physiological threshold after 291 which the net totality of deviation of these biomarkers from norm can be considered a disease.
293
Set effective metrics. When performing cost-effectiveness analysis (CBA), economists often 294 evaluate the outcomes of various programs in terms of the quality-adjusted life years (QALYs) 295 and healthy-years equivalent (HYE) (Mehrez and Gafni, 1989) . The most effective altruistic 296 causes are now also evaluated using these metrics (Macaskill, 2015) . Studies also demonstrate 297 that each QALY can be valued at $24,777 to $428,286 depending on the method (Hirth et al., There are definite benefits for many stakeholders in having aging classified as a disease, and the 306 research community should consider uniting and working as a single voice to increase the chance 307 of having aging classified as a disease by the WHO. (1980) . Report of the WHO/ISFC task force on the definition and classification of with age; relationship between aging and age-associated diseases. Am J Clin Nutr 55, 592 1225s-1230s.
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